Question

The nurse is assessing a client who has undergone a percutaneous transluminal coronary angioplasty (PTCA) and is ordered to receive an IV infusion of abciximab (ReoPro). Which clinical manifestation does the nurse monitor for in this client?

a. Bleeding
b. Joint pain
c. Pedal edema
d. Excessive thirst

Answer 1

The nurse should monitor the client for bleeding as a potential side effect of receiving an IV infusion of abciximab (ReoPro) after undergoing a percutaneous transluminal coronary angioplasty (PTCA).

Step-by-step explanation:

The nurse should monitor the client for bleeding as a potential side effect of receiving an IV infusion of abciximab (ReoPro) after undergoing a percutaneous transluminal coronary angioplasty (PTCA). Abciximab is an antiplatelet medication, and it works by preventing platelets from sticking together and forming clots. While this can help prevent clot formation in the coronary arteries, it can also increase the risk of bleeding. Therefore, the nurse should closely observe the client for any signs of bleeding, such as unusual bruising, bleeding gums, or blood in the urine or stool.